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Little is known about the molecular machinery that contributes to site-specific copy number varia-
tions or howCNVs fit into the chronology of tumor progression. Black et al. (2013) now demonstrate
that the overexpression of a histone demethylase induces transient copy gain of specific genomic
loci known to harbor proto-oncogenes.DNA replication is a tightly regulated
and highly coordinated process that min-
imizes incorporation of mismatched
nucleotides and ensures that each DNA
strand is faithfully replicated exactly
once per cell cycle. This vital task is
shared between thousands of separate
replicons to accommodate timely
genome replication (Pope et al., 2013).
Molecular analyses of replication demon-
strate that not all replicons behave the
same in regard to replication timing
during S phase. Transcriptionally active,
gene-rich domains replicate during the
first half of S phase (early), whereas tran-
scriptionally repressed, gene-poor loci
replicate in the second half of S phase
(late). Furthermore, alterations in repli-
cation timing accompany key stages of
development (Hiratani et al., 2009).
In addition to diverse roles of histone
modifications in the regulation of gene
expression (Lee et al., 2010), there are
close links between posttranslational
histone modifications and the cell cycle
(Schulze et al., 2009). Studies utilizing
chromatin immunoprecipitation followed
by next-generation sequencing (ChIP-
seq) suggest a role for covalent chromatin
modifications in regulating early versus
late replicating domains (Schwaiger
et al., 2009). It has also been hypothe-
sized that DNA replication is regulated at
the chromatin level, where histone modi-
fications recruit factors that impede DNA
replication (Black et al., 2010). Chromatin
regions lacking these histone modi-
fications are more accessible to the
replication machinery and are therefore
more likely to be mistakenly rereplicated.
In a previous study, Whetstine and
colleagues demonstrated that the levels
of KDM4A/JMJD2, a histone H3K9 andH3K36-specific demethylase, are regu-
lated during S phase and that KDM4A
overexpression increases chromatin
accessibility while altering replication
timing of specific genomic loci (Black
et al., 2010). In this issue, they demon-
strate that KDM4A overexpression in-
duces copy number gains at specific
loci, such as 1q12, which contain putative
oncogenes (Black et al., 2013). Though
KDM4A overexpression was previously
reported in a small set of cancers (Mallette
and Richard, 2012), Black and colleagues
extend this list by analyzing the Cancer
Genome Atlas (TCGA) for tumors contain-
ing increased KDM4A copy numbers and
expression levels (Black et al., 2013). They
identify ovarian cancer as being signifi-
cantly enriched for KDM4A copy number
amplification in 46% of the tumor sam-
ples. Although they were unable to detect
copy gains by spectral karyotyping, upon
reanalyzing previous KDM4A ChIP-chip
data, they identify enrichments for cyto-
genetic bands such as 1q12 as a result
of KDM4A overexpression. Fluorescent
in situ hybridization (FISH) experiments
in KDM4A-overexpressing cells confirm
the copy number increase while ruling
out whole-chromosome duplications.
Importantly, this site-specific copy gain
coamplifies with KDM4A in primary tumor
samples.
To investigate the molecular mecha-
nism linking KDM4A and copy number
variation (CNV), Black et al., overexpress
KDM4A point mutants and find that the
Jumonji catalytic domain and both Tudor
domains are required for CNV. To exclude
the possibility that KDM4A functions
through a histone-independent pathway,
the authors coexpress histone H3 mu-
tants with methionine in place of eitherCell 1lysine 9 or 36 (H3K9M, H3K36M). Histone
mutants that interfere with H3K9/36
methylation recapitulate the KDM4A-
dependent CNV phenotype, indicating
that KDM4A histone-demethylase acti-
vity plays a direct role in this process.
Additionally, KDM4A immunoprecipita-
tion resulted in the identification of inter-
acting proteins such as members of the
minichromosome maintenance (MCM)
complex and several DNA polymerase
subunits. The authors speculate that
KDM4A promotes unlicensed replication
via bypassing the need for the origin of
replication complex (ORC) formation via
direct MCM and DNA polymerase recruit-
ment (Figure 1).
Previously, Black et al. identified
HP1g as an antagonist of KDM4A-depen-
dent S-phase progression (Black et al.,
2010). Here, they further characterize
this antagonism by showing that HP1g
overexpression disrupts KDM4A-depen-
dent CNV. HP1g contains a chromodo-
main that binds methylated histone
H3K9. Therefore, HP1g is able to block
KDM4A demethylation, creating a ‘‘steric
blockade’’ that prevents local DNA repli-
cation. Consistent with this hypothesis,
overexpression of H3K9 methyltransfer-
ase Suv39h1/KMT1A is also able to sup-
press 1q12 copy gains.
Finally, to determine whether 1q12
copy gains are stably inherited by
daughter cells, single-cell clones from
KDM4A-overexpressing cell lines were
generated. Strikingly, when performing
1q12 FISH, only 17% of cells contain the
1q12 copy gain, indicating that KDM4A-
dependent copy gains are not stably
inherited by daughter cells. By arresting
KDM4A-overexpressing cells at either
G1/S or G2, it was determined that copy54, August 1, 2013 ª2013 Elsevier Inc. 477
Figure 1. KDM4AOverexpressionPromotesLocalDNARereplication
(A) HP1g binds to methylated H3K9, blocking access to KDM4A and the DNA
replication machinery.
(B) To properly coordinate replication timing, KDM4A demethylates H3K9,
promoting local DNA accessibility.
(C) When overexpressed, KDM4A demethylase activity maintains different
regions of chromatin in an uncondensed state, promoting aberrant DNA
rereplication (red lines). Black et al. hypothesize that the extrachromosomal
DNA copies result from head-to-tail polymerase collisions.gains are generated during
S phase but disappear by
G2 via an undetermined
mechanism. This suggests
that the copy gains are not
incorporated into the genome
but, rather, exist as extrachro-
mosomal DNA. Intriguingly,
the 1q12/21 regions contain
several proto-oncogenes,
including Mcl1 and Bcl9, and
this region is frequently
amplified in lung cancer and
multiple myeloma. In addition,
1q12/21 copy gains are asso-
ciated with drug resistance
in ovarian cell lines and multi-
ple myeloma, underscoring
the significance of under-
standing the relationship
between KDM4A and 1q12/
21 coamplification in human
health.
Chromosome copy number
alterations are thought to
be important for acquired
cellular plasticity by allowing
a precancerous cell to amplify
genes that are required for
proliferation, angiogenesis,
and evasion of cell death.
The discovery of KDM4A
overexpression as a driver
of CNV has uncovered a
potential mechanistic link
between local chromatin
structure/composition and
DNA rereplication with copy
number variation. Histone
H3K9 trimethylation, the sub-
strate for KDM4A, is associ-
ated with both active and
repressed gene states. A role
for histone H3K9 methylation
and HP1-g in this process is
very exciting; however, it is
unclear whether KDM4A’s
role in cancer pathogenesis
is due to its function at
heterochromatin or through
the transcriptional elongation
regulatory function associ-
ated with H3K9 trimethy-
lation. Among the three iso-
forms of HP1 (a, b, and g),HP1- g is found on transcriptionally active
regions (Smith and Shilatifard, 2007).
Because KDM4A demethylates histone478 Cell 154, August 1, 2013 ª2013 ElsevierH3K36, a chromatin mark associated
with the elongating and active form of
RNA polymerase II (Smith and Shilatifard,Inc.2007), a role for the mis-
regulation of transcription
elongation control in cancer
pathogenesis through CNV
as a result of KDM4A over-
expression should also be
considered. Indeed, aberrant
transcriptional elongation
checkpoint control has been
proposed as a key regulatory
mechanism for leukemic
pathogenesis through chro-
mosomal translocations and
other forms of cancer (Smith
and Shilatifard, 2013).
Although it is currently un-
known how KDM4A is initially
amplified in tumors, one can
imagine how KDM4A over-
expression might eventually
result in 1q12/21 copy gains
becoming stably incorpo-
rated into the genome. It is
not clear whether the con-
tinual passaging of KDM4A-
expressing cells eventually
leads to stable 1q12/21 copy
gain inheritance. If so, what
is the statistical likelihood of
such an event? How does
this likelihood change when
DNA damage is induced?
Do these cells have a com-
petitive advantage over cells
having only transient copy
gains? Most importantly,
does 1q12/21 amplification,
independent of KDM4A over-
expression, result in cancer
pathogenesis, or are other
unidentified genomic regions
responsible for the postulated
role of KDM4A in cancer?
Moreover, how does KDM4A
specificity for the 1q12/21 re-
gion arise? Is H3K9M/K36M-
induced CNV restricted to
1q12/21, or are there more
broadly distributed replica-
tion defects? This outstand-
ing study by Black and
colleagues raises many stim-
ulating questions and may
cause a shift in our thinking
and understanding of therole of chromatin-modifying/demodifying
enzymes—as they apply to not only
transcriptional regulation, but also DNA
replication and genome stability. The very
exciting identification of KDM4A overex-
pression and its association with ovarian
cancer clearly has provided the field with
yet another chromatin-modifying enzyme
that can be used as a possible therapeutic
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ER-associated degradation clears the secretory pathway of misfolded proteins and mediates the
regulated degradation of some ER resident proteins. Only a minor increase in the interaction
between a protein and a ubiquitin ligase is sufficient to signal substrate degradation. Zhang et al.
have identified deubiquitination as a signal amplifier.The decision to destroy misfolded pro-
teins in the cell is not made lightly, as
there is always the hope that proteins
having transitional conformations may
simply be en route to their native struc-
tures. This is especially true in the secre-
tory pathway because soluble misfolded
substrates are recognized in the lumen
of the endoplasmic reticulum (ER) and
then must be exported into the cyto-
plasm, where they are destroyed via
the ubiquitin-proteasome pathway. This
process is known as ER-associated
degradation (ERAD). The ERAD of integral
membrane proteins presents a special
challenge, as membrane-spanning do-
mains must be liberated from the lipid
bilayer before the protein is threadedinto the 26S proteasome. Genetic and
in vitro analyses have delineated the
varied pathways taken during the degra-
dation of membrane proteins, with the
spotlight directed at E3 ligases that
append ubiquitin onto a proteasome-tar-
geted substrate. In this issue of Cell,
Hegde and colleagues redirect the spot-
light toward an opposing reaction, the
processive removal of the polyubiquitin
chain, which amplifies subtle differences
in E3-client interactions to generate a
polyubiquitin chain that is sufficient
for proteasome-mediated degradation
(Zhang et al., 2013).
Mammals encode > 600 E3s, so one
might envision that each E3 recognizes a
misfolded conformation adopted by asubset of the proteome (Varshavsky,
2012). In turn, each protein might be iden-
tified by a select group of E3s. Indeed,
functional redundancy among E3-client
interactions is frequently observed. How-
ever, due to complexities inherent in the
folding pathway, a protein displays a
range of misfolded conformations. More-
over, previous studies uncovered rela-
tively minor differences in the recognition
of an ERAD substrate versus its wild-
type counterpart by an E3 ubiquitin ligase
(Gardner et al., 2001; Ishikura et al., 2010;
Meacham et al., 2001). How are these
differences magnified to ensure that
folding-competent proteins do not fall
victim to the ubiquitin-proteasome sys-
tem or do so rarely?54, August 1, 2013 ª2013 Elsevier Inc. 479
